[go: up one dir, main page]

MX2019013750A - Un metodo para producir ranibizumab humanizado recombinante replegado. - Google Patents

Un metodo para producir ranibizumab humanizado recombinante replegado.

Info

Publication number
MX2019013750A
MX2019013750A MX2019013750A MX2019013750A MX2019013750A MX 2019013750 A MX2019013750 A MX 2019013750A MX 2019013750 A MX2019013750 A MX 2019013750A MX 2019013750 A MX2019013750 A MX 2019013750A MX 2019013750 A MX2019013750 A MX 2019013750A
Authority
MX
Mexico
Prior art keywords
recombinant humanized
ranibizumab
refolded recombinant
producing
producing refolded
Prior art date
Application number
MX2019013750A
Other languages
English (en)
Inventor
Rahul Sharad Bhambure
Kayanat Mahammadtaki Gani
Original Assignee
Council Scient Ind Res
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Council Scient Ind Res filed Critical Council Scient Ind Res
Publication of MX2019013750A publication Critical patent/MX2019013750A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/22—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
    • C12P21/00—Preparation of peptides or proteins
    • C12P21/02—Preparation of peptides or proteins having a known sequence of two or more amino acids, e.g. glutathione
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biophysics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Microbiology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)

Abstract

La presente invención se refiere a un novedoso proceso de clonación, expresión y repliegue para preparar fragmentos de anticuerpo; mas particularmente, la presente invención se refiere a una plataforma de clonación, expresión y repliegue para preparar 5 Ranibizumab humanizado recombinante (rHu).
MX2019013750A 2017-05-19 2018-05-18 Un metodo para producir ranibizumab humanizado recombinante replegado. MX2019013750A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
IN201711017654 2017-05-19
PCT/IN2018/050315 WO2018211529A1 (en) 2017-05-19 2018-05-18 A method for producing refolded recombinant humanized ranibizumab

Publications (1)

Publication Number Publication Date
MX2019013750A true MX2019013750A (es) 2020-07-20

Family

ID=62599663

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2019013750A MX2019013750A (es) 2017-05-19 2018-05-18 Un metodo para producir ranibizumab humanizado recombinante replegado.

Country Status (9)

Country Link
US (2) US11524996B2 (es)
EP (1) EP3624847A1 (es)
JP (1) JP7282689B2 (es)
KR (1) KR102607655B1 (es)
CN (1) CN110636859B (es)
BR (1) BR112019023795A2 (es)
CA (1) CA3063320A1 (es)
MX (1) MX2019013750A (es)
WO (1) WO2018211529A1 (es)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2020202208A1 (en) * 2019-04-02 2020-10-08 Council Of Scientific & Industrial Research Cloning and expression of in-vivo refolded antibody fragment
EP3981879A1 (en) * 2020-10-09 2022-04-13 Stada Arzneimittel Ag Method of producing a recombinant protein in a host cell which has a disabled rhamnose metabolism as well as expression vectors, host cells and recombinant proteins thereof

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7399837B2 (en) * 1995-12-22 2008-07-15 Smithkline Beecham Corporation Recombinant IL-5 antagonists useful in treatment of IL-5 mediated disorders
JP3957765B2 (ja) 1997-04-07 2007-08-15 ジェネンテク・インコーポレイテッド 抗ｖｅｇｆ抗体
JP2003102494A (ja) * 2001-07-26 2003-04-08 Sangaku Renkei Kiko Kyushu:Kk 蛋白質のリフォールディング方法及び連続リフォールディング方法並びに連続リフォールディング装置
JP2008512085A (ja) * 2004-06-03 2008-04-24 ネオス テクノロジーズ インコーポレイティッド 切断型ＧａｌＮＡｃＴ２ポリペプチドおよび核酸
ZA200900229B (en) 2006-07-14 2010-04-28 Genentech Inc Refolding of recombinant proteins
JP2010528664A (ja) * 2007-06-08 2010-08-26 ダウ グローバル テクノロジーズ インコーポレイティド Ｃｈ１ドメインの切断による可溶性抗体断片の発現
HRP20170615T1 (hr) 2008-06-25 2017-07-28 Esbatech, An Alcon Biomedical Research Unit Llc Stabilna i topiva protutijela koja inhibiraju vegf
IN2014MN00935A (es) 2011-11-22 2015-04-24 Lupin Ltd
CN113896787A (zh) * 2011-12-22 2022-01-07 弗·哈夫曼-拉罗切有限公司 表达载体元件组合、新的生产用细胞产生方法及其在重组产生多肽中的用途
CN102757496B (zh) * 2012-06-07 2014-06-18 山东泉港药业有限公司 一种抗vegf抗体片段的纯化制备方法
EP2992021B1 (en) * 2013-04-30 2020-07-22 Intas Pharmaceuticals Limited Novel cloning, expression & purification method for the preparation of ranibizumab
EP3167065B1 (en) * 2014-07-09 2020-03-25 Lupin Limited Dual cistronic bacterial expression system
LT3337820T (lt) * 2015-08-17 2021-02-10 Lupin Limited Patobulintas antikūnų fragmentų refoldingo būdas

Also Published As

Publication number Publication date
US20200140535A1 (en) 2020-05-07
CN110636859A (zh) 2019-12-31
KR102607655B1 (ko) 2023-11-28
BR112019023795A2 (pt) 2020-07-28
US20200165332A1 (en) 2020-05-28
JP7282689B2 (ja) 2023-05-29
WO2018211529A1 (en) 2018-11-22
US11578122B2 (en) 2023-02-14
CA3063320A1 (en) 2018-11-22
CN110636859B (zh) 2024-05-03
US11524996B2 (en) 2022-12-13
EP3624847A1 (en) 2020-03-25
KR20200008147A (ko) 2020-01-23
JP2020520642A (ja) 2020-07-16

Similar Documents

Publication Publication Date Title
PH12020550214A1 (en) Antibodies specific to cd47 and pd-l1
MX2021005254A (es) Produccion recombinante de una preparacion de peptido de colageno y uso de la misma.
MX2021003580A (es) Nuevas inmunocitocinas para el tratamiento contra el cancer.
PH12020550076A1 (en) Aerosol-generating material rod segment
MX2019011916A (es) Anticuerpos anti-lag3.
PE20180481A1 (es) Anticuerpos de union a tau
PH12019502298A1 (en) Monoclonal antibody to pd-l1
MX2019010769A (es) Proceso para la preparacion de enlazadores de farmacos de glucuronidos y compuestos intermediarios de los mismos.
PH12020550927A1 (en) Therapeutic enzyme fusion protein having novel structure and use thereof
MX368142B (es) Metodo de clonacion, expresion y purificacion novedoso para la preparacion de ranibizumab.
TW201613967A (en) Interferon alpha and omega antibody antagonists
PH12020500054A1 (en) Novel therapeutic enzyme fusion protein and use thereof
MX2019008241A (es) Un enlazador polipeptídico para preparar anticuerpos multispecíficos.
MX2019000415A (es) Procedimiento para la produccion de una vacuna de adn para inmunoterapia del cancer.
AU2015348922A8 (en) Codon optimized polynucleotide for high level expression of CRM197
BR112021011529A2 (pt) Método para produção de um anticorpo heterodimérico, e, anticorpo biespecífico isolado
MX382952B (es) Métodos de producción de proteínas de cadena doble en bacterias.
MX2021004454A (es) Anticuerpos anti-sinucleina.
MX2017005730A (es) Metodos para mejoramiento de plantas.
PH12020550218A1 (en) MONOCLONAL ANTIBODY TO IL-5Ra
MX376061B (es) Anticuerpos contra antìgeno de plaqueta 1a humano (hpa-1a).
MX2019013750A (es) Un metodo para producir ranibizumab humanizado recombinante replegado.
MX2019007978A (es) Mezcla para la fabricacion de un producto ceramico refractario no moldeado, procedimiento para la fabricacion de un producto ceramico refractario no moldeado asi como un producto ceramico refractario no moldeado fabricado por ello.
MX2022002563A (es) Nuevo promotor y metodo para producir la sustancia deseada usando el mismo.
MX2018013562A (es) Metodo de produccion de una proteina recombinante.